Mair Therapeutics
Recent Finacing
Pre-Seed
Recent Raise
Undisclosed
Mair Therapeutics is a biotechnology company developing TMEM175-targeting small molecules for Parkinson's by combining ion-channel modulation expertise, computational discovery tools, and collaborations with Radboud University plus accelerator in Nijmegen.
Highlights
Focus Areas
Biopharma
Biotechnology
Clinical Trials
Personal Development
Recent Investors
Financials
1
Funding round
2
Investors